Tailored psychological intervention for anxiety or depression in COPD (TANDEM): a randomised controlled trial.

Autor:	Taylor SJC; Wolfson Institute of Population Health, Queen Mary University of London, London, UK s.j.c.taylor@qmul.ac.uk.; Joint first authors., Sohanpal R; Wolfson Institute of Population Health, Queen Mary University of London, London, UK.; Joint first authors., Steed L; Wolfson Institute of Population Health, Queen Mary University of London, London, UK., Marshall K; Chest Clinic, RVI Hospital, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK., Chan C; Wolfson Institute of Population Health, Queen Mary University of London, London, UK., Yaziji N; Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK., Barradell AC; NIHR Leicester Biomedical Research Centre - Respiratory, Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK., Font-Gilabert P; Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK., Healey A; Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK., Hooper R; Wolfson Institute of Population Health, Queen Mary University of London, London, UK., Kelly MJ; Wolfson Institute of Population Health, Queen Mary University of London, London, UK., Mammoliti KM; WHO Collaborating Centre on Global Women's Health, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK., Priebe S; Wolfson Institute of Population Health, Queen Mary University of London, London, UK., Rajasekaran A; Department of Respiratory Medicine, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK., Roberts CM; Centre for Digital Transformation of Health, University of Melbourne, Melbourne, Australia., Rowland V; Department of Population Health, School of Life Course and Population Sciences, King's College London, London, UK., Singh SJ; Department of Respiratory Sciences, Department of Health Sciences, University of Leicester, Leicester, UK., Smuk M; Blizard Institute, Queen Mary University of London, London, UK., Underwood M; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.; University Hospitals of Coventry and Warwickshire, Coventry, UK., Waseem S; Women's Health Division, University College Hospital, London, UK., White P; Department of Population Health, School of Life Course and Population Sciences, King's College London, London, UK., Wileman V; Health Psychology, School of Mental Health and Psychological Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK., Pinnock H; Allergy and Respiratory Research Group, Usher Institute, The University of Edinburgh, Edinburgh, UK.
Jazyk:	angličtina
Zdroj:	The European respiratory journal [Eur Respir J] 2023 Nov 02; Vol. 62 (5). Date of Electronic Publication: 2023 Nov 02 (Print Publication: 2023).
DOI:	10.1183/13993003.00432-2023
Abstrakt:	Background: The TANDEM multicentre, pragmatic, randomised controlled trial evaluated whether a tailored psychological intervention based on a cognitive behavioural approach for people with COPD and symptoms of anxiety and/or depression improved anxiety or depression compared with usual care (control). Methods: People with COPD and moderate to very severe airways obstruction and Hospital Anxiety and Depression Scale subscale scores indicating mild to moderate anxiety (HADS-A) and/or depression (HADS-D) were randomised 1.25:1 (242 intervention and 181 control). Respiratory health professionals delivered the intervention face-to-face over 6-8 weeks. Co-primary outcomes were HADS-A and HADS-D measured 6 months post-randomisation. Secondary outcomes at 6 and 12 months included: HADS-A and HADS-D (12 months), Beck Depression Inventory II, Beck Anxiety Inventory, St George's Respiratory Questionnaire, social engagement, the EuroQol instrument five-level version (EQ-5D-5L), smoking status, completion of pulmonary rehabilitation, and health and social care resource use. Results: The intervention did not improve anxiety (HADS-A mean difference -0.60, 95% CI -1.40-0.21) or depression (HADS-D mean difference -0.66, 95% CI -1.39-0.07) at 6 months. The intervention did not improve any secondary outcomes at either time-point, nor did it influence completion of pulmonary rehabilitation or healthcare resource use. Deaths in the intervention arm (13/242; 5%) exceeded those in the control arm (3/181; 2%), but none were associated with the intervention. Health economic analysis found the intervention highly unlikely to be cost-effective. Conclusion: This trial has shown, beyond reasonable doubt, that this cognitive behavioural intervention delivered by trained and supervised respiratory health professionals does not improve psychological comorbidity in people with advanced COPD and depression or anxiety. Competing Interests: Conflict of interest: L. Steed reports support for the present manuscript from the NIHR Health Technology Assessment programme (project number 13/146/02), and also reports lecture honoraria from the IPCRG, outside the submitted work. K. Marshall reports support for the present manuscript from the NIHR Health Technology Assessment programme (project number 13/146/02), and also reports lecture honoraria, outside the submitted work. S.J. Singh reports support for the present manuscript from the NIHR Health Technology Assessment programme (project number 13/146/02); in addition, S.J. Singh also reports grants from the NIHR (NIHR 202020 and senior investigator grant), Wellcome Doctoral Training Programme, HTA Project Grant (NIHR 131015), NIHR DHSC/UKRI COVID-19 Rapid Response Initiative, NIHR Global Research Group (NIHR 17/63/20) and Actegy Limited, lecture honoraria from GSK, Ministry of Justice, CIPLA and Sherbourne Gibbs, advisory board participation with NICE (Expert Adviser Panel – Long COVID) and the Wales Long COVID Advisory Board (expired), and leadership roles with the ATS (Pulmonary Rehabilitation Assembly Chair), RCP Pulmonary Rehabilitation Accreditation Scheme and NACAP Audit for Pulmonary Rehabilitation, outside the submitted work. M. Underwood is chief investigator or co-investigator on previous and current research grants from the UK NIHR, Arthritis Research UK and on grants funded by the Australian NHMRC and Norwegian MRC; he was an NIHR Senior Investigator until March 2021. He has received travel expenses for speaking at conferences from the professional organisations hosting the conferences. He is a director and shareholder of Clinvivo Ltd. He is part of an academic partnership with Serco Ltd, funded by the European Social Fund. He is a co-investigator studies that are, or have had, additional support from Stryker Ltd. Until March 2020 he received a fee as an NIHR journal editor and editors group member. V. Wileman reports support for the present manuscript from the NIHR Applied Research Collaboration (ARC) North Thames. P. White is a chief investigator or co-investigator on multiple previous and current research grants from the NIHR, and reports travel expenses for speaking at conferences from the professional organisations hosting the conferences. H. Pinnock reports support for the present manuscript from the NIHR Health Technology Assessment programme (project number 13/146/02), and also reports lecture honoraria from Sandoz, Teva and Boehringer Ingelheim, outside the submitted work. S.J.C. Taylor, R. Sohanpal, S. Priebe, A. Healey, S. Waseem, M.J. Kelly and C.M. Roberts report support for the present manuscript from the NIHR Health Technology Assessment programme (project number 13/146/02). All other authors have nothing to disclose. (Copyright ©The authors 2023.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu